Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

swift107 May. 15 at 8:13 PM

$FBIOP my strategy was buying before the PRV cash hit the 10Q financial statements. Even amongst biotech people the common stock of $FBIO is unknown and difficult to understand given the structure and being sub $100M makes it non institutional. Therefore retail and small funds will find it with their screeners AFTER the financial release data shows negative EV and the balance sheet cash dwarfing mcap. THEN will some of those folks discover FBIOP and see the no brainer of having a company with sizeable cash that can easily repay the prefs, that will in 1-2Qs have positive earnings, and increasing royalties that have no real cost. What made Fbiop a no brainer to us long timers will now be discovered by others as an incredibly lucrative investment. I think we’ll see it at $18 very quickly and I would expect activists (hopefully not Tang Capital) come in to push for better cash utilization at FBIO including restarting dividends.

2 · Reply

JFais May. 15 at 3:36 PM

$FBIO - green on a very red day for $XBI, noteworthy behavior (preferred $FBIOP going up as well)

3 · Reply

CabinFever208 May. 15 at 3:30 PM

$FBIOP Like the cash on head now, and that Journey Medical is turning cash flow positive with lower SG&A expenses.

0 · Reply

StockBodega May. 15 at 1:38 PM

$FBIO $FBIOP As of April 30, 2026, Fortress Biotech (FBIO) has a significant short interest of 4.65 million shares, representing 19.58% of the public float. This high short interest, combined with a 17.8-day cover ratio, suggests a potential for high volatility or a short squeeze, particularly with a 46.55% price increase over the past year. [1, 2, 3] Key Short Interest Metrics (April 30, 2026 Report): Short Interest: 4,649,541 shares. Percent of Float: 19.58%. Short Interest Ratio (Days to Cover): 17.8 days. Change vs. Previous Month: +2.26%. [1]

0 · Reply

Chaka1647 May. 15 at 12:04 PM

$FBIOP Not suprised but still annoyed by lack of dividends But still go back to this ... it is way undervalued even if you assume payment not til 28 and 20% chance it is worth zero. And I personally still think it is getting current for next year 10k I wonder if at some point the preferred holders exercise their rights to get on the BOD as a threat.

1 · Reply

makrodimutross May. 14 at 8:45 PM

$FBIO $FBIOP Mexican standoff until company makes good to FBIOP holders.

3 · Reply

Alex1m2 May. 14 at 8:33 PM

$FBIOP Why is this trading at 14$? Is it because it is a very small company and nobody knows it? Aren't there HedgeFunds that buy this kind of stuff? Can someone explain this to me?

2 · Reply

Alex1m2 May. 14 at 8:20 PM

$FBIOP Results are out. As of March 31, 2026, Fortress’ consolidated cash and cash equivalents totaled $255.8 million Are you fucking kidding me? Where are our dividends!

1 · Reply

makrodimutross May. 14 at 2:03 PM

$DERM $FBIO $FBIOP The jury is in. On the heels of excellent growth indicators for EMROSI, The market remains relentless with its punishment of FBIO for their neglect of the preferred stockholders. If 100m cash isnt enough to reinstate dividends, what IS enough? BOD better provide Q1 guidance, or i see a 1.xx handle for FBIO in the near future.

2 · Reply

Chaka1647 May. 13 at 1:20 PM

Should be an interesting 24 hours for $FBIO and $FBIOP Keep in mind that I don't think they need to catch up on the dividend until before they publish the 10k (March 27) if they want the ability to raise under the shelf next year. I think if you are just worried about that ... you collect the interest on your cash and pay out later. But if you are worried about $FBIO apprecation being held back by lack of divys, you reinstate now

2 · Reply

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

FBIOP

May 13, 2026, 4:01 PM EDT - 2 days ago

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A